Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Current Deferred Revenue (2017 - 2025)

Historic Current Deferred Revenue for Arcus Biosciences (RCUS) over the last 9 years, with Q3 2025 value amounting to $105.0 million.

  • Arcus Biosciences' Current Deferred Revenue fell 7335.03% to $105.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $105.0 million, marking a year-over-year decrease of 7335.03%. This contributed to the annual value of $319.0 million for FY2024, which is 1984.92% down from last year.
  • According to the latest figures from Q3 2025, Arcus Biosciences' Current Deferred Revenue is $105.0 million, which was down 7335.03% from $131.0 million recorded in Q2 2025.
  • In the past 5 years, Arcus Biosciences' Current Deferred Revenue ranged from a high of $429.0 million in Q3 2023 and a low of $35.0 million during Q2 2023
  • In the last 5 years, Arcus Biosciences' Current Deferred Revenue had a median value of $103.3 million in 2022 and averaged $189.3 million.
  • As far as peak fluctuations go, Arcus Biosciences' Current Deferred Revenue surged by 96530.0% in 2021, and later plummeted by 7335.03% in 2025.
  • Over the past 5 years, Arcus Biosciences' Current Deferred Revenue (Quarter) stood at $102.0 million in 2021, then fell by 4.9% to $97.0 million in 2022, then skyrocketed by 310.31% to $398.0 million in 2023, then fell by 19.85% to $319.0 million in 2024, then plummeted by 67.08% to $105.0 million in 2025.
  • Its Current Deferred Revenue stands at $105.0 million for Q3 2025, versus $131.0 million for Q2 2025 and $291.0 million for Q1 2025.